|
|
Article: Safeguard Scientifics Leads $17.4 Million Series B Financing for Quinnova Pharmaceuticals.
- Article from:
- Business Wire
- Article date:
- October 28, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Patented technology addresses unmet need in dermatology for enhanced treatment compliance and therapeutic efficacy
WAYNE, Pa. -- Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced it led a $17.4 million Series B financing round for Quinnova Pharmaceuticals, Inc., with participation from existing investors Thomas, McNerney & Partners and H.I.G. BioVentures. Quinnova will use the proceeds to fund a Phase III clinical trial for an NDA product, expand its sales and marketing capabilities, facilitate the company's other NDA and medical device clinical trials, and fund ...
Related newspaper, magazine, and journal articles:
|
|
Article: Quinnova Pharmaceuticals, Inc. Launches Salvax ...
Biotech Week;
January 21, 2009 ;
700+ words
...Quinnova Pharmaceuticals, Inc. announced the launch ... inflammatory properties (see also Quinnova Pharmaceuticals, Inc.). oSalvax (Hydrating ... the United States. About Quinnova Pharmaceuticals, Inc. Quinnova Pharmaceuticals ...
|
|